

Aralez Pharmaceuticals Inc.
Form 8-K
September 15, 2016

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 15, 2016**

ARALEZ PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada
(State or other jurisdiction of
incorporation)

001-37691
(Commission File Number)

98-1283375
(IRS Employer Identification No.)

7100 West Credit Avenue, Suite 101, Mississauga,
Ontario, Canada

L5N 0E4

Edgar Filing: Aralez Pharmaceuticals Inc. - Form 8-K

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: **(905) 876-1118**

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On September 15, 2016, Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada (the Company), issued a press release announcing that the U.S. Food and Drug Administration (the FDA) has approved YOSPRALA for the secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin-associated gastric ulcers. The full text of such press release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

The Company will conduct a conference call today, Thursday, September 15, 2016 at 11:00 a.m. ET, to discuss the approval of YOSPRALA by the FDA. The presentation slides to be used during the call will be available on the Investors section of the Company's website (<http://www.aralez.com>) under the Presentations & Webcasts tab beginning at 11:00 a.m. ET on Thursday, September 15, 2016. A question and answer session will follow the presentation. The conference call and the presentation slides will be simultaneously webcast on the Investors section of the Company's website under the Presentations & Webcasts tab beginning at 11:00 a.m. ET on Thursday, September 15, 2016 and will remain available for future review for two weeks after the event. The information contained in, or that can be accessed through, the Company's website is not a part of this filing.

Item 9.01. Financial Statements and Exhibits

(d) List of Exhibits

**EXHIBIT
NO.**

DESCRIPTION

99.1 Press Release, dated September 15, 2016, issued by Aralez Pharmaceuticals Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 15, 2016

ARALEZ PHARMACEUTICALS INC.

By: */s/ Eric L. Trachtenberg*
Eric L. Trachtenberg
General Counsel, Chief Compliance Officer and
Corporate Secretary

EXHIBIT INDEX

EXHIBIT NO.	DESCRIPTION
99.1	Press Release, dated September 15, 2016, issued by Aralez Pharmaceuticals Inc.